Please assess the completion status of the following clinical trial:

Trial Title: Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ages 18-60 years~* Absence of HIV-1 and HCV antibodies at screening,~* Ability and willingness to give written informed consent before the first trial-related activity.~Exclusion Criteria:~* Pregnancy~* Breastfeeding~* Active alcohol or drug abuse that, in the opinion of the investigators, would interfere with adherence to study requirements~* Participation in any investigational drug study within 30 days prior to study entry~* Currently active or chronic gastrointestinal, cardiovascular, neurologic, psychiatric, metabolic, renal, hepatic, respiratory, inflammatory, or infectious disease or malignancy requiring pharmacologic treatment, and/or if in the opinion of the investigator, would affect study participation, safety, or integrity of results~* Use of concomitant medication, including investigational, prescription, and over-the-counter products and dietary supplements with the following exceptions: aspirin, acetaminophen, ibuprofen, hormonal oral contraceptives~* Concomitant medications other than those listed above must have been discontinued at least 14 days before study entry~* Currently active dermatitis or urticaria or diagnosis of eczema or psoriasis,~* History of significant drug allergy (i.e., anaphylaxis and/or angioedema)~* Subjects with the following laboratory abnormalities at screening as defined by the 2004 Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS grading table) and in accordance with the normal ranges of the trial clinical laboratory: serum creatinine grade 1 or greater (≥ 1.1 x upper limit of laboratory normal range (ULN)); hemoglobin grade 1 or greater (≤ 10.9 g/dL); platelet count grade 1 or greater (≤ 124.999 x 109/L); absolute neutrophil count grade 1 or greater (≤ 1.3 x 109/L); aspartate aminotransferase (AST) or alanine aminotransferase (ALT) grade 1 or greater (≥ 1.25 x ULN); total bilirubin grade 1 or greater (≥ 1.1 x ULN), any other laboratory abnormality of grade 2 or above.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Sequence 1a (Type: EXPERIMENTAL): Sequence 1,2,3: simeprevir only, then dolutegravir only, then both simeprevir and dolutegravir.
- Sequence 1b (Type: EXPERIMENTAL): Sequence 1,3,2: simeprevir only, then both simeprevir and dolutegravir, then dolutegravir only.
- Sequence 2a (Type: EXPERIMENTAL): Sequence 2,1,3: dolutegravir only, then simeprevir only, then both simeprevir and dolutegravir.
- Sequence 2b (Type: EXPERIMENTAL): Sequence 2,3,1: dolutegravir only, then both simeprevir and dolutegravir, then simeprevir only.
- Sequence 3a (Type: EXPERIMENTAL): Sequence 3,1,2: both simeprevir and dolutegravir, then simeprevir only, then dolutegravir only.
- Sequence 3b (Type: EXPERIMENTAL): Sequence 3,2,1: Both simeprevir and dolutegravir, then dolutegravir only, then simeprevir only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete